Semaglutide → Decreased appetite — Audit-grade candidate (scan)

← All findings ⬇ Download signed audit packet

Ledger entry · candidate

Semaglutide → Decreased appetite — Audit-grade candidate (scan)

Drug: semaglutide · AE: Decreased appetite

Discovered via single-drug scan of semaglutide. PRR = 5.65 (95% CI 5.39–5.92), n = 1637 cases. Pre-reg locked at submission time.

Disproportionality

PRR: 5.651751212196847 (95% CI 5.39–5.92)
Yates χ²: 6287.634815912135
Cases (case-drug + AE): n = 1637
Verdict: PASSES_ALL_GATES — PRR=5.65 (95% CI 5.39–5.92), n=1637 cases; flagged for clinical expert review, NOT for external escalation without manual verification

Top reactions in cohort

MedDRA PT	n
No reactions surfaced in cohort.

Source: openFDA FAERS, Caliper Engine v0. Pre-registration sha1 locked at submission time; ledger entry signed with platform Ed25519 key.

Independent Verification & Validation

Every finding includes an in-engine adversary review at no cost. For findings you plan to cite in a regulatory submission, scientific publication, or board-grade decision, we offer an additional layer of independent, audit-grade verification — reviewed by an externally-trained system that has never seen your data, your training corpus, or our hardware, and cryptographically signed.

Reference: d6cffa71c7cd8c28b6d9243ae1a0be23d2db0136